Johnson & Johnson $JNJ Stake Lessened by Triglav Investments D.O.O.

Triglav Investments D.O.O. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,900 shares of the company’s stock after selling 1,600 shares during the period. Triglav Investments D.O.O.’s holdings in Johnson & Johnson were worth $9,302,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. GFG Capital LLC acquired a new stake in Johnson & Johnson during the second quarter valued at approximately $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter valued at $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the 1st quarter worth about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.0%

JNJ stock opened at $189.02 on Friday. The firm’s 50-day moving average is $183.28 and its two-hundred day moving average is $167.66. The company has a market capitalization of $455.40 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s payout ratio is 50.19%.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. HSBC boosted their price objective on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Citigroup upped their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Bank of America raised their target price on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research note on Wednesday, October 15th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.